Cibc World Markets Corp bought a new position in shares of Integer Holdings Co. (NYSE:ITGR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 3,120 shares of the medical equipment provider's stock, valued at approximately $413,000.
Other large investors have also added to or reduced their stakes in the company. Intech Investment Management LLC purchased a new stake in shares of Integer in the third quarter worth approximately $1,012,000. Charles Schwab Investment Management Inc. grew its holdings in Integer by 1.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 404,029 shares of the medical equipment provider's stock worth $52,524,000 after buying an additional 4,946 shares in the last quarter. Eagle Asset Management Inc. purchased a new stake in Integer in the 3rd quarter valued at $14,403,000. Cerity Partners LLC lifted its stake in Integer by 11.5% during the 3rd quarter. Cerity Partners LLC now owns 32,961 shares of the medical equipment provider's stock valued at $4,285,000 after acquiring an additional 3,389 shares in the last quarter. Finally, Larson Financial Group LLC boosted its holdings in Integer by 20,000.0% during the 3rd quarter. Larson Financial Group LLC now owns 1,005 shares of the medical equipment provider's stock worth $131,000 after acquiring an additional 1,000 shares during the last quarter. Institutional investors own 99.29% of the company's stock.
Integer Stock Performance
NYSE:ITGR traded down $0.33 on Thursday, reaching $117.74. 415,188 shares of the company's stock were exchanged, compared to its average volume of 316,466. The stock has a fifty day simple moving average of $131.40 and a 200-day simple moving average of $132.12. Integer Holdings Co. has a 52 week low of $107.11 and a 52 week high of $146.36. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. The firm has a market cap of $3.96 billion, a price-to-earnings ratio of 35.04, a P/E/G ratio of 1.72 and a beta of 1.24.
Integer (NYSE:ITGR - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The business had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. As a group, sell-side analysts predict that Integer Holdings Co. will post 6.01 earnings per share for the current year.
Analyst Ratings Changes
Several research firms recently weighed in on ITGR. Benchmark boosted their price target on shares of Integer from $140.00 to $150.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Oppenheimer lowered Integer from an "outperform" rating to a "market perform" rating in a report on Friday, February 21st. Truist Financial increased their price target on Integer from $147.00 to $163.00 and gave the company a "buy" rating in a research report on Wednesday, December 11th. KeyCorp boosted their price objective on Integer from $144.00 to $154.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Finally, Citigroup raised their target price on Integer from $130.00 to $145.00 and gave the company a "neutral" rating in a research report on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $149.00.
Check Out Our Latest Report on Integer
Integer Company Profile
(
Free Report)
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
Featured Stories
Before you consider Integer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integer wasn't on the list.
While Integer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
